000 02360 a2200577 4500
005 20250515154555.0
264 0 _c20090430
008 200904s 0 0 eng d
022 _a1699-048X
024 7 _a10.1007/s12094-009-0311-4
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aG Estevez, L
245 0 0 _aDoxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study.
_h[electronic resource]
260 _bClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
_cJan 2009
300 _a54-9 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAged, 80 and over
650 0 4 _aAntigens, Neoplasm
_xbiosynthesis
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aBiomarkers, Tumor
_xanalysis
650 0 4 _aBreast Neoplasms
_xdrug therapy
650 0 4 _aCyclophosphamide
_xadministration & dosage
650 0 4 _aDNA Topoisomerases, Type II
_xbiosynthesis
650 0 4 _aDNA-Binding Proteins
_xbiosynthesis
650 0 4 _aDocetaxel
650 0 4 _aDoxorubicin
_xadministration & dosage
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aImmunohistochemistry
650 0 4 _aInhibitor of Apoptosis Proteins
650 0 4 _aMicrotubule-Associated Proteins
_xbiosynthesis
650 0 4 _aMiddle Aged
650 0 4 _aNeoadjuvant Therapy
_xmethods
650 0 4 _aNeoplasm Staging
650 0 4 _aProliferating Cell Nuclear Antigen
_xbiosynthesis
650 0 4 _aSurvivin
650 0 4 _aTaxoids
_xadministration & dosage
700 1 _aFortes, J L
700 1 _aAdrover, E
700 1 _aPeiró, G
700 1 _aMargel, M
700 1 _aCastellá, E
700 1 _aCuevas, J M
700 1 _aBernet, L
700 1 _aSegui, M A
700 1 _aAndreu, X
773 0 _tClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
_gvol. 11
_gno. 1
_gp. 54-9
856 4 0 _uhttps://doi.org/10.1007/s12094-009-0311-4
_zAvailable from publisher's website
999 _c18602382
_d18602382